The MarketReader Minute
đź’Š JANX Surges on Prostate Cancer Trial Success, REGN Slides and RVMD Dips on Secondary Offering News | Biotech Sector Insights
(IBB) has experienced a decline of 0.7% since Monday. Significant contributors to this downturn include Moderna (MRNA), which dropped notably, along with Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX)